This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Lexicon's CEO Presents At Wedbush PacGrow 2012 Life Sciences Management Access Conference (Transcript)

So that's from the source of all these compounds in development. As you can see, we have quite an extensive and growing pipeline. Again, I'll spend most of the time on our diabetes programs and then I'll only describe briefly, have time for our serotonin programs and carcinoid syndrome and IBS at the end.

So let's turn to diabetes then. 4211, this is a very unique compound. It's the first-in-class agent in that it blocks both SGLT1 and 2. These are the two key transporters in the body that handle glucose. So it affects the glucose load in the body. And SGLT1 target is the primary transporter in the GI tract and this is I think brings us 4211 the unique attributes that I'll describe.

SGLT2 is a better known target. It's under development at a number of companies. It's the main transporter in the kidney and it controls the rate of glucose, the reabsorption from the urine back into the blood. But together we have found these transporters work in a coordinated fashion really to regulate the glucose -- overall glucose load in the body. And by blocking them, we can reduce that load.

In the GI tract, you reduce the amount of glucose that comes into the body and also trigger other beneficial mechanisms including Glip 1 and then with SGLT2, you can actually offload more glucose into the urine.

Now the industry has really, as I said, mostly focused on SGLT2 as you can see by this column to the right, a number of large companies with their partners. And the reason they avoided SGLT1 in the beginning is there was a theoretical concern that blocking that target might cause GI side effects. Indeed, there are humans lacking SGLT1 and a complete lack of the target does lead to a glucose-galactose malabsorption syndrome. And so that put off researchers from that target.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs